NEW YORK (GenomeWeb) – Sciex today announced a comarketing agreement with EluciData, a provider of tools for metabolomics data processing.
Under the terms of the agreement, Sciex will promote EluciData's Polly multi-omics platform in conjunction with its TripleTOF, X500R QTOF, and QTRAP instruments and its Differential Ion Mobility technologies.
Financial terms of the deal were not disclosed.
"Improving the efficiency of metabolomics workflows is critical if academic researchers and pharma customers want to advance precision medicine," Mark Cafazzo, Sciex director of strategic market management, said in a statement. "The use of Polly with Sciex metabolomics workflows accelerates their capabilities and empowers them to spend more time on the biology than on crunching data through fragmented software tools."
Polly is a cloud-based end-to-end platform that standardizes and streamlines metabolomics data analysis workflows and integrates other forms of omics data.
The agreement follows other deals EluciData has made for its platform. In December 2018, for example, the firm signed a four-year contract with Auron Therapeutics to provide data analytics.